RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY OF VE202 IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS

Brief description of study

This is a phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate Ulcerative Colitis (UC). The duration of the study for each study patient is approximately 56 weeks (up to 4 weeks for screening and vancomycin pretreatment, and 52 weeks from the time of the first dose of VE202 or placebo until completion of the last follow-up visit).


Clinical Study Identifier: s23-00089
Principal Investigator: Jordan E Axelrad.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.